Impact of arterio–ventricular interaction on first-phase ejection fraction in aortic stenosis

Eigir Einarsen 1*, Johannes J. Hjertaas1, Haotian Gu2, Knut Matre1, Philip J. Chowienczyk2, Eva Gerds1,3, John B. Chambers4, and Sahrai Saeed3

1Department of Clinical Science, University of Bergen, Bergen, Norway; 2British Heart Foundation Centre, King’s College London, London, UK; 3Department of Heart Disease, Haukeland University Hospital, Bergen, Norway; and 4Cardiothoracic Centre, Guy’s and St Thomas’ Hospital, London, UK

Aims
First-phase ejection fraction (EF1), the EF at the time to peak aortic jet velocity, has been proposed as a novel marker of peak systolic function in aortic stenosis (AS). This study aimed to explore the association of myocardial contractility and arterial load with EF1 in AS patients.

Methods and results
Data from a prospective, cross-sectional study of 114 patients with mild, moderate, and severe AS with preserved left ventricular EF (>50%) were analysed. EF1 was measured as the volume change from end-diastole to the time that corresponded to peak aortic jet velocity. Myocardial contractility was assessed by strain rate measured by speckle tracking echocardiography. Arterial stiffness was assessed by central pulse pressure/stroke volume index ratio (PP/SVi). The total study population included 48% women, median age was 73 years, and mean peak aortic jet velocity was 3.47 m/s. In univariable linear regression analyses, lower EF1 was associated with higher age, higher peak aortic jet velocity, lower global EF, lower global longitudinal strain, lower strain rate, and higher PP/SVi. There was no significant association between EF1 and heart rate or sex. In multivariable linear regression analysis, EF1 was associated with lower strain rate and higher PP/SVi, independent of AS severity. Replacing PP/SVi by valvular impedance did not change the results.

Conclusion
In patients with AS, reduced myocardial contractility and increased arterial load were associated with lower EF1 independent of the severity of valve stenosis.

Keywords
aortic stenosis • ejection fraction • myocardial function • arterial stiffness

Introduction
Aortic stenosis (AS) is the most common cause of aortic valve replacement in developed countries. Once symptoms occur or there is a reduction in left ventricular ejection fraction (LVEF) <50%, the current guidelines recommend aortic valve intervention. The transition to symptoms partly reflects maladaptive compensatory mechanisms, particularly characterized by myocardial fibrosis which may not reverse following aortic valve replacement. However, in AS it is well known that LVEF may be preserved by compensatory remodelling and hypertrophy, despite reduced myocardial contractility. Recently, the first-phase EF (EF1), a measurement of the LVEF at the time of peak aortic jet velocity, has emerged as a novel marker of early LV systolic impairment both in hypertension and AS patients. Early and accurate recognition of subclinical LV systolic dysfunction offers the potential to optimize the timing of intervention in AS. In patients with moderate or severe AS, lower EF1 showed incremental prognostic value compared with LVEF and global longitudinal strain. However, more information on the underlying factors influencing EF1 is needed. In particular, the interaction between EF1 with myocardial contractility and increased arterial load was associated with lower EF1 independent of AS severity.
arterial load needs further exploration. Increased arterial load is highly prevalent in AS patients due to higher age, hypertension, and large arterial stiffening. Previous studies have documented the association of arterial stiffness with impaired myocardial function. This study aimed at exploring the associations between myocardial contractility and arterial load with EF1 in AS.

Methods

Study population
We prospectively recruited 120 patients with AS from the outpatient clinic, Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, between October 2015 and December 2017. Patients were considered eligible if they had at least mild AS defined as aortic valve thickening and peak aortic jet velocity >2 m/s. Exclusion criteria were cardiac arrhythmias, prior pacemaker implantation, other concomitant valvular disease of more than moderate grade, known coronary artery disease (myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention), or previous cardiac surgery. Patients with reduced LVEF (<50%) (n = 3) were excluded from the present analysis. The study was approved by the local Regional Committee for Medical and Health Research Ethics, and was conducted in accordance with the Declaration of Helsinki. All patients signed a written informed consent prior to study examinations.

Cardiovascular risk factors
Following inclusion, all participants underwent a clinical examination at the outpatient clinic. Before the echocardiographic examination, brachial blood pressure (BP) was measured in triplicate with 1-minute intervals after an initial 5-minute rest in the seated position using a regularly calibrated aneroid sphygmomanometer and appropriate cuff size. The average of the last two measurements was taken as the clinic BP. Hypertension was defined as use of antihypertensive medication, history of hypertension, or clinical BP ≥140/90 mmHg. Self-reported health was recorded on a standardized questionnaire including information on cardiovascular risk factors, medication, and known diseases and was quality assured by study personnel.

Echocardiography
A standardized transthoracic echocardiogram was performed in all patients using a Vivid 9 scanner (GE Vingmed Ultrasound, Horten, Norway). Digital images were stored and analysed at the Bergen Echocardiographic Core Laboratory using TomTec workstations equipped with Image Arena 4.6 software (TomTec, Unterschleissheim, Germany). Conventional measurements in all studies were first analysed by the same reader (E.E.) and later proof-read by an experienced reader (E.G.). Quantitative assessment of the LV and AS severity were performed according to the joint European Association of Echocardiography and American Society of Echocardiography recommendations. LV mass was calculated using the Devereux formula, and indexed to body height in the allometric power of 2.7 to obtain LV mass index. LV hypertrophy was defined by the prognostically validated cut-off values of LV mass index >49.2 g/m2.7 in men and LV mass index >46.7 g/m2.7 in women. LVEF was calculated using the Simpson biplane method. Peak aortic jet velocity was measured from different acoustic windows including the use of a stand-alone probe, and the highest velocity was used for tracing of the time-velocity integral. The effective aortic orifice area was calculated by the continuity equation. Mild AS was defined as peak aortic jet velocity of 2.0–2.9 m/s, moderate AS as peak aortic jet velocity of 3.0–3.9 m/s, and severe AS as peak aortic jet velocity ≥4.0 m/s.

Stroke volume (SV) was assessed by Doppler and indexed for body surface area, as recommended by the guidelines. Central pulse pressure (PP) was estimated using a validated formula: brachial PP × 0.49 + age × 0.30 + 7.11. Arterial stiffness was estimated by the ratio from central PP/SV index (PP/SVi). Global LV load was assessed from valvuloarterial impedance (Zva), calculated as systolic BP + mean aortic pressure gradient/SVi. Peak systolic annular velocities were measured by tissue Doppler imaging at the medial and lateral annulus, and averaged to obtain peak S'. EF1 was measured by the biplane method of discs by measuring the volume change from end-diastole to the time that corresponded to peak aortic jet velocity by spectral Doppler. EF1 was thus derived by:

\[
EF1 = \frac{(EDV - V1)}{EDV}
\]

where EDV is the LV volume at end-diastole and V1 is the LV volume at the time corresponding to peak aortic jet velocity in the cardiac cycle (Figure 1). EF1 was measured manually at the exact frame of peak aortic
jet velocity by taking into account the frame rate and time in milliseconds from aortic valve opening to peak aortic jet velocity.

Two-dimensional speckle tracking echocardiography and EF1 analyses were performed offline on a dedicated workstation equipped with EchoPac BT 202 (GE Vingmed Ultrasound, Horten, Norway), using apical two-, three-, and four-chamber views with frame rate optimized to 60–90 frames/s (median 74 frames/s, mean 73 frames/s). The endocardial border of the LV was traced, and the region of interest was adjusted at the epicardial border per segment, as appropriate. After software processing, tracking quality was checked visually, and all segments were adjusted manually if needed. The time of aortic valve closure was measured from a pulsed wave Doppler recording in the LV outflow tract, and was defined as the end of systole. Drift compensation was used during analysis, and smoothing parameters were kept at default. Global longitudinal strain was calculated as the average peak negative longitudinal shortening from the 18 LV segments. Longitudinal strain rate values from the 18 LV segments were averaged to obtain peak systolic strain rate.

Diastolic function was defined in accordance with current guidelines,20 in all analyses.

Statistical analyses

Statistical analyses were performed using IBM SPSS version 25.0 (IBM, Armonk, NY, USA). The study population was divided into three groups: mild, moderate, and severe AS. Findings are reported as mean ± standard deviation for continuous variables and as percentages for categorical variables. Normal distribution was checked prior to analyses by Q–Q plots and normality tests (Kolmogorov–Smirnov). Groups were compared by analysis of variance (ANOVA) with Schefè’s post-hoc test for continuous variables and by general linear model with Sidak’s post-hoc test for categorical variables, respectively. Covariates of EF1 were identified in univariable and multivariable linear regression analyses using an enter or stepwise procedure. The core assumptions of normality of the error distribution, homoscedasticity, and linearity were tested and not violated. Multicollinearity was assessed by the variance of inflation factor. Results are presented as standardized β-coefficients and P values. Goodness of fit is expressed as the adjusted R². Independent covariates of EF1 <25% were tested in univariable and multivariable binary logistics regression analyses. Results are presented as odds ratio (OR) and 95% confidence interval (CI). Goodness of fit was tested with Hosmer–Lemeshov’s test. For intra- and interobserver variability, intraclass correlation coefficients were calculated to assess agreement between EF1 measurements. Intra- and interobserver variability of EF1 measurements were assessed in 18 randomly selected subjects by repeated analyses 3 months after initial reading. A two-tailed P value <0.05 was considered statistically significant in all analyses.

Results

A total of 120 patients (48% women) were recruited and median age was 73 years (age range 31–94 years). Six patients were excluded, three because of suboptimal echocardiographic images, and three due to reduced LVEF (<50%), leaving 114 patients eligible for the inclusion in the present analysis. 16 patients (nine with severe AS and seven with moderate AS) had mild symptoms. Among those with symptomatic severe AS, six patients received aortic valve intervention, one patient was offered aortic valve replacement but declined, while two patients were considered not eligible for valve replacement due to severe comorbidities including cancer. The prevalence

### Table 1  Clinical characteristics across patients with mild, moderate, and severe AS

|                        | Mild (n = 38) | Moderate (n = 44) | Severe (n = 32) | P (ANOVA) |
|------------------------|--------------|------------------|----------------|-----------|
| Age (years)            | 72 ± 10      | 71 ± 12          | 76 ± 9         | 0.133     |
| Sex (male)             | 45%          | 57%              | 47%            | 0.513     |
| Systolic blood pressure (mmHg) | 153 ± 25    | 146 ± 18         | 143 ± 15       | 0.063     |
| Diastolic blood pressure (mmHg) | 84 ± 11     | 83 ± 7           | 79 ± 9*        | 0.036     |
| Heart rate (bpm)       | 66 ± 10      | 68 ± 9           | 71 ± 12        | 0.119     |
| Body surface area (m²) | 1.89 ± 0.19  | 1.91 ± 0.24      | 1.84 ± 0.23    | 0.278     |
| Weight (kg)            | 78 ± 14      | 78 ± 18          | 72 ± 16        | 0.159     |
| Height (cm)            | 170 ± 10     | 171 ± 9          | 170 ± 9        | 0.803     |
| Body mass index (kg/m²)| 26.9 ± 4.1   | 26.6 ± 4.6       | 25.0 ± 3.8     | 0.066     |
| Hypertension, n (%)    | 33 (90)      | 40 (91)          | 29 (88)        | 0.912     |
| Diabetes, n (%)        | 5 (13)       | 6 (14)           | 2 (6)          | 0.563     |
| Current smokers, n (%) | 1 (3)        | 4 (9)            | 3 (9)          | 0.109     |
| Symptoms, n (%)        | 0 (0)        | 7 (16)           | 9 (28)*        | 0.011     |
| NYHA functional class, n (%) | 2          | 0 (0)            | 6 (14)         | 8 (25)    |
|                        | 3            | 0 (0)            | 1 (2)          | 1 (3)     |
| Hypercholesterolaemia, n (%) | 7 (18) | 9 (20)           | 7 (22)         | 0.938     |

NYHA, New York Heart Association; bpm, beats per minute.

*P < 0.05 vs. mild AS.
of hypertension was 89.5%, diabetes 11.4%, hypercholesterolemia 46.5%, and diastolic dysfunction 25.4%. Clinical characteristics between groups of mild, moderate, and severe AS did not differ, except for diastolic BP which was lower in patients with severe AS (Table 1).

Patients with severe AS had significantly higher LV mass index and relative wall thickness (both \(P < 0.05\)). Global longitudinal strain, LVEF, and SVI did not differ between groups (Table 2). Indices of peak LV systolic function, including acceleration time, strain rate, and EF1 all progressively declined from mild to severe AS (all \(P < 0.05\)) (Table 2 and Figure 2). Filling pressure \((E/e')\) increased in parallel with the increasing AS severity grade \(P < 0.05\).

The intraobserver correlation coefficient for EF1 was \(0.94 (95\% \text{ CI } 0.85–0.98)\) for intraobserver variability and \(0.88 (95\% \text{ CI } 0.67–0.95)\) for interobserver variability, reflecting excellent reproducibility. In univariable linear regression analyses in the total study population, lower EF1 was associated with higher LV mass index, older age, and end-systolic wall stress (Table 3). Lower EF1 was also associated with lower global longitudinal strain, lower strain rate, and with higher peak aortic jet velocity. Higher EF1 was associated with a higher peak \(S'\). In bivariate analyses, EF1 was negatively correlated with higher \(Zva\) \((r = -0.33, P < 0.001)\), PP/SVi \((r = -0.29, P = 0.002)\), higher central PP \((r = -0.29, P = 0.002)\), higher brachial PP \((r = -0.25, P = 0.009)\), and with symptoms \((r = -0.34, P < 0.001)\). No association between hypertension and EF1 was detected \((P = 0.123)\). In multivariable linear regression, lower EF1 was associated with lower strain rate independent of age, peak aortic jet velocity, LV mass index, diastolic dysfunction, and LVEF (Table 3, Model 1). In Model 2, lower EF1 was associated with higher PP/SVi independent of age, peak aortic jet velocity, LVEF, and global longitudinal strain (Table 3). Replacing PP/SVi by Zva did not change the results. In Model 3, we included all

### Table 2  Echocardiographic characteristics across patients with mild, moderate, and severe AS

|                       | Mild (\(n = 38\)) | Moderate (\(n = 44\)) | Severe (\(n = 32\)) | \(P\) (ANOVA) |
|-----------------------|-------------------|-----------------------|---------------------|---------------|
| Peak aortic jet velocity (m/s) | 2.5 ± 0.3 | 3.5 ± 0.3* | 4.6 ± 0.5** | <0.001 |
| Mean aortic gradient (mmHg) | 13 ± 3.5 | 26 ± 4.1* | 50 ± 13** | <0.001 |
| Aortic valve area (cm²) | 1.83 ± 0.34 | 1.26 ± 0.32* | 0.91 ± 0.21** | <0.001 |
| Zva (mmHg/mL/m²) | 2.9 ± 0.8 | 3.3 ± 0.9 | 3.6 ± 0.8* | 0.001 |
| LV end-diastolic diameter (mm) | 47 ± 6 | 47 ± 6 | 45 ± 6 | 0.246 |
| LV end-systolic diameter (mm) | 31 ± 5 | 31 ± 5 | 29 ± 5 | 0.116 |
| Septal wall thickness (mm) | 13 ± 2 | 13 ± 3 | 16 ± 3** | <0.001 |
| Posterior wall thickness (mm) | 9 ± 1 | 10 ± 2 | 11 ± 2* | 0.014 |
| Relative wall thickness | 0.41 ± 0.08 | 0.42 ± 0.09 | 0.48 ± 0.10** | 0.003 |
| LV hypertrophy (%) | 34 | 39 | 56 | 0.151 |
| LV mass (g) | 195 ± 59 | 198 ± 65 | 235 ± 90 | 0.040 |
| LV mass index (g/m²) | 46.2 ± 11.9 | 45.6 ± 11.6 | 54.8 ± 16.0** | 0.006 |
| PP/SVi (mmHg/mL/m²) | 1.19 ± 0.29 | 1.17 ± 0.34 | 1.20 ± 0.28 | 0.922 |
| Meridional end-systolic stress (dyne/cm²) | 179 ± 37 | 184 ± 42 | 192 ± 41 | 0.376 |
| Systolic function | \[\text{Global ejection fraction (\%)}\] | 63 ± 4 | 62 ± 5 | 64 ± 5 | 0.216 |
| \[\text{Global longitudinal strain (\%)}\] | -20.5 ± 2.0 | -20.0 ± 2.3 | -19.1 ± 3.2 | 0.061 |
| \[\text{Peak } S' (\text{cm/s})\] | 8.1 ± 1.6 | 7.8 ± 1.2 | 7.0 ± 1.2** | 0.002 |
| \[\text{Stroke volume index (mL/m²)}\] | 55 ± 10 | 52 ± 10 | 55 ± 11 | 0.319 |
| \[\text{Global longitudinal strain rate (s⁻¹)}\] | -1.05 ± 0.16 | -1.03 ± 0.15 | -0.94 ± 1.17* | 0.017 |
| \[\text{Mechanical dispersion (ms)}\] | 44 ± 12 | 43 ± 17 | 57 ± 21** | 0.001 |
| \[\text{First-phase ejection fraction (\%)}\] | 31 ± 4 | 30 ± 4 | 27 ± 4** | <0.001 |
| Diastolic function | \[\text{Filling pressure (E/e')}\] | 11.1 ± 5.5 | 12.4 ± 5.2 | 13.9 ± 4.6* | 0.010 |
| \[\text{Peak } e' (\text{cm/s})\] | 6.9 ± 1.6 | 6.9 ± 1.5 | 5.7 ± 1.2** | <0.001 |
| \[\text{Tricuspid jet (m/s)}\] | 2.47 ± 0.47 | 2.59 ± 0.33 | 2.54 ± 0.38 | 0.460 |
| \[\text{Left atrial volume index (mL/m²)}\] | 33.5 ± 8.5 | 36.0 ± 12.3 | 38.9 ± 11.6 | 0.139 |
| \[\text{Diastolic dysfunction, n (\%)}\] | 5 (11) | 13 (30) | 11 (36)* | 0.036 |
| Ejection dynamics | \[\text{Acceleration time (ms)}\] | 78 ± 17 | 93 ± 18* | 111 ± 15** | <0.001 |
| \[\text{Ejection time (ms)}\] | 314 ± 31 | 313 ± 27 | 323 ± 36 | 0.353 |
| \[\text{Acceleration/ejection time ratio}\] | 0.25 ± 0.05 | 0.30 ± 0.05* | 0.35 ± 0.05** | <0.001 |

LV, left ventricular; ms, milliseconds; PP/SVi, pulse pressure/stroke volume index; Zva, valvuloarterial impedance.

*\(P < 0.05\) vs. mild AS

**\(P < 0.05\) vs. mild and moderate AS.
significant variables from the univariable analyses in a stepwise procedure. Lower strain rate, higher peak aortic jet velocity and higher PP/SVi all remained as significant and independent covariates of EF1 (all \( P < 0.05 \)) (Table 3). Higher acceleration time was also associated with lower EF1 in univariable analysis (\( \beta = -0.46, P < 0.001 \)). Due to a strong collinearity between peak aortic jet velocity and acceleration time, these two variables were not included in the same multivariable model. However, replacing peak aortic jet velocity with acceleration time in secondary models, did not change the results, and the association between EF1 and acceleration time remained significant in all multivariable models (data not shown). When restricting analyses only to moderate and severe AS groups, the association between PP/SVi and EF1 in multivariable stepwise regression became stronger (\( \beta = -0.35, P < 0.001 \)), the association between peak velocity and EF1 slightly attenuated (\( \beta = -0.27, P = 0.006 \)), while the association between EF1 and strain rate remained unchanged (\( \beta = -0.39, P < 0.001 \)).

In univariable logistic regression analysis, EF1 < 25% was associated with higher mechanical dispersion (OR = 1.03, \( P = 0.022 \)), but after multivariable adjustment the association was attenuated (\( P > 0.05 \)). In multivariable logistic regression analysis, EF1 < 25% shared the same covariates as for EF1 in a continuous scale (Table 4).

**Discussion**

The detection of early myocardial dysfunction in AS may be challenging. After the development of symptoms, there is a sharp increase in the risk of irreversible myocardial damage and mortality. Irreversible myocardial damage is often referred to as midwall fibrosis on late gadolinium enhanced cardiac magnetic resonance imaging, which is common in AS and reduces the survival benefit of aortic valve replacement.\(^{21}\) EF1, a measure of peak systolic LV function, has been shown to predict outcome more precisely than the traditional markers of end-systolic LV function like LVEF and global longitudinal strain in patients with AS.\(^{15}\) The present study adds to previous knowledge by demonstrating that EF1 progressively declined with increasing AS severity, and that lower EF1 was associated with lower global longitudinal strain rate and higher PP/SVi independent of AS severity.

**The association between EF1 and strain rate**

Cardiomyocyte contraction occurs predominantly in the first part of systole and peaks approximately at the time of peak aortic jet velocity. It has been demonstrated that strain rate and peak aortic jet velocity are almost simultaneous events in the cardiac cycle,\(^{22}\) and their respective timing intervals in early systole corresponds well with peak force development in individual cardiomyocytes.\(^{23}\) In line with these findings, we observed a closer association between EF1 and peak strain rate than with global longitudinal strain and EF1 in the present study.

Even though strain rate does not directly measure peak myocardial contraction per se, the relationship between strain rate and contractility has been shown in an experimental pig model.\(^{24}\) Weidemann et al. demonstrated that while strain rate was related to contractility, global longitudinal strain was more closely related to SV and LVEF.\(^{25}\) EF1 and strain rate are measures of peak systolic performance, and are therefore less load dependent, and more closely related to contractility, which is in line with our findings. In contrast, end-systolic measures, such as LVEF and global longitudinal strain, are more associated with maximal LV load which is reached in late systole. As demonstrated by our results, EF1 showed a progressive reduction from mild to severe AS while LVEF remained within the normal range across all grades of AS severity. Similarly, EF1 was also closely related to peak \( S' \), a reliable marker of systolic function that has been closely related to contractility.\(^{26}\)

Peak systolic indices are also better markers of changes in inotropic alterations.\(^{26}\) Strain rate often remains constant during an increase in heart rate, suggesting that it is relatively independent of heart rate variations.\(^{26}\) Similarly, no correlation between heart rate and EF1 was detected in this study.

Strain rate has been shown to be affected by both preload and afterload, but to a lesser degree than end-systolic markers.\(^{27}\) In this regard, it is inevitable that EF1 to a certain degree is load dependent due to its close correlation with strain rate. This is reflected by our findings, as EF1 remained associated with peak strain rate independent of both PP/SVi and AS severity, together representing the total arterial- and valvular load on the LV. Thus, lower EF1 is not just a consequence of afterload excess, but reflects impairment in intrinsic myocardial systolic contractility. These results are in line with previous research demonstrating that in severe AS patients, the ratio between wall stress and LVEF is significantly reduced, indicating reduced contractility.\(^{28}\) This highlights the fact that watchful waiting for spontaneous symptoms in some patients with severe AS may lead to irreversible damage in LV myocardium. As recommended by the guidelines, valve replacement is recommended in patients with asymptomatic very severe AS (peak jet velocity > 5.5 m/s).\(^{29}\) We
variable relationship between EF1 and filling pressure. We corroborate previous findings by demonstrating a significant unipense of an impaired early systolic function and diastolic relaxation. Early systole might prolong contraction, preserving LVEF at the expense of a time-varying systolic load on LV function. The increased tension in arteries at the time corresponding to EF1. This underlines the importance of reflections increase the pulsatile load in mid-systole, and may occur as an important covariate of EF1. In patients with arterial stiffness, the higher PP/SVi, a surrogate of arterial stiffness, was identified in patients with asymptomatic severe AS and normal LVEF in the future.

**The association between EF1 and arterial stiffness**

In AS, increased LV load is caused by combined arterial and valvular resistance. Increased arterial load in AS is commonly caused by hypertension and/or increased arterial stiffness. Interestingly, in this study higher PP/SVi, a surrogate of arterial stiffness, was identified as an important covariate of EF1. In patients with arterial stiffness, the reflected-wave reaches the proximal aorta in early systole, boosting systolic BP and increasing myocardial oxygen demand. Early wave reflections increase the pulsatile load in mid-systole, and may occur at the time corresponding to EF1. This underlines the importance of time-varying systolic load on LV function. The increased tension in early systole might prolong contraction, preserving LVEF at the expense of an impaired early systolic function and diastolic relaxation. We corroborate previous findings by demonstrating a significant univariable relationship between EF1 and filling pressure.

In our data, EF1 correlated better with the estimated central PP than with brachial PP. This is in line with previous findings which showed that central aortic PP was a better predictor of target organ damage. Higher PP/SVi has also been demonstrated as an independent predictor of cardiovascular events and all-cause mortality in hypertensive patients. Furthermore, one could speculate that the arterio–ventricular coupling demonstrated in the current study, could contribute to the observed impaired prognosis in AS patients with reduced arterial compliance.

**Limitations**

This study was small and performed in AS patients with acceptable image quality, and assessment may be less feasible and reproducible in patients with poor acoustic windows. In addition, cause–effect relations cannot be determined due to the cross-sectional study design. PP/SVi is an echocardiographic surrogate of arterial stiffness. The relationship between EF1 and a more direct and accurate measure of arterial stiffness, such as the gold standard pulse wave velocity, should be tested in larger outcome studies in the future.

EF1 was significantly associated with self-reported symptoms. However, the true prevalence of symptoms in our study cohort may have been underestimated since a treadmill exercise test was not

---

**Table 3  Linear regression analyses of covariates of first-phase ejection fraction**

| Covariate                              | Univariable | Multivariable model 1 | Multivariable model 2 | Multivariable model 3 |
|----------------------------------------|-------------|------------------------|------------------------|------------------------|
|                                        | Standardized | P value                | Standardized | P value                | Standardized | P value | Standardized | P value | Standardized | P value | P value |
| Global longitudinal strain rate (s⁻¹) | -0.50        | <0.001                 | -0.38        | <0.001                 | -0.40        | <0.001 |
| PP/SVi (mmHg/mL/m²)                    | -0.29        | 0.002                  | -0.27        | 0.003                  | -0.28        | <0.001 |
| Peak aortic jet velocity (m/s)         | -0.41        | <0.001                 | -0.26        | 0.003                  | -0.36        | <0.001 |
| Age (years)                            | -0.28        | 0.003                  | 0.21         | 0.011                  | 0.241        | NS      |
| Global ejection fraction (%)           | 0.18         | 0.059                  | 0.13         | 0.106                  | 0.15         | 0.059   |
| Left ventricular mass index (g/m²)     | -0.24        | <0.001                 | 0.11         | 0.833                  | 0.02         | NS      |
| Diastolic dysfunction (yes/no)         | -0.29        | 0.002                  | -0.09        | 0.284                  | NS           | NS      |
| Filling pressure (E/e⁰)                | -0.27        | 0.004                  |              |                        | NS           | NS      |
| Global longitudinal strain (%)         | -0.40        | <0.001                 | -0.28        | 0.001                  | NS           | NS      |
| Peak S' (cm/s)                         | 0.46         | <0.001                 |              |                        | NS           | NS      |
| End-systolic wall stress (dyne/cm²)    | -0.26        | 0.005                  |              |                        | NS           | NS      |
| Acceleration time (ms)                 | -0.46        | <0.001                 |              |                        | NS           | NS      |
| Body mass index (kg/m²)                | 0.18         | 0.060                  |              |                        | NS           | NS      |
| Heart rate (bpm)                       | -0.07        | 0.469                  |              |                        | NS           | NS      |
| Hypertension (yes/no)                  | -0.15        | 0.123                  |              |                        | NS           | NS      |
| Mechanical dispersion (ms)             | -0.15        | 0.127                  |              |                        | NS           | NS      |
| Systolic blood pressure (mmHg)         | -0.15        | 0.077                  |              |                        | NS           | NS      |
| Zva (mmHg/mL/m²)                       | -0.33        | <0.001                 |              |                        | NS           | NS      |
| Relative wall thickness ratio           | -0.12        | 0.188                  |              |                        | NS           | NS      |
| Posterior wall thickness (mm)          | -0.20        | 0.033                  |              |                        | NS           | NS      |
| Septal wall thickness (mm)             | -0.21        | 0.027                  |              |                        | NS           | NS      |
| Acceleration/ejection time ratio       | -0.38        | <0.001                 |              |                        | NS           | NS      |

Model 1: multiple R² 0.37, P < 0.001; Model 2: multiple R² 0.37, P < 0.001; Model 3: multiple R² 0.40, P < 0.001. Model 1: multivariable model of the association between EF1 and global longitudinal strain rate. Model 2: multivariable model of the association between EF1, global longitudinal strain and PP/SVi. Model 3: multivariable stepwise regression model, including all significant variables from univariable analyses.

ms, milliseconds; NS, not significant; bpm, beats per minute; PP/SVi, pulse pressure/stroke volume index; Zva, valvulo-arterial impedance.
performed to assess revealed symptoms. In our study, there was some overlap in EF1 across mild, moderate and severe AS, which might limit its application in patients with less severe AS. This needs to be studied in larger studies with less severe AS. Coronary artery disease is common in AS patients. Although known coronary artery disease was an exclusion criterion by design, we cannot exclude that asymptomatic coronary artery disease may have been present in some participants with reduced EF1. In severe AS, higher serum B-type natriuretic peptide has been independently associated with some participants with reduced EF1. In severe AS, higher serum B-type natriuretic peptide has been independently associated with lower global longitudinal strain.33 However, B-type natriuretic peptide was not measured in the present study, and the relation to EF1 could therefore not be assessed. Lastly, both EF1 and strain rate values were derived from the B-mode frame rate. This could lead to inaccuracies in the measurement of EF1 and underestimation of strain rate. However, we have carefully optimized the frame rate and achieved an acceptable frame rate which is above the recommended frame rate threshold for strain rate measurements.

Conclusions
In patients with varying degree of AS, severity, lower myocardial contractility and higher arterial stiffness were both associated with lower EF1, a marker of peak systolic function, independent of AS severity.

Data availability
The data underlying this article will be shared on reasonable request to the corresponding author.

Conflict of interest: none declared.

Acknowledgements
We thank Doctor Marina Kokorina and study nurse Liv Himle for their invaluable help in data acquisition.

Table 4  Uni- and multivariable logistic regression analyses of covariates of first-phase ejection fraction <25%

|                        | Univariable OR (95% CI) | P value | Multivariable OR (95% CI) | P value |
|------------------------|-------------------------|---------|---------------------------|---------|
| PP/SVi (mmHg/mL/m²) (per 1SD) | 1.61 (1.05–2.48) | 0.029   | 1.89 (1.08–3.31) | 0.026   |
| Strain rate (s⁻¹) (per 1SD decline) | 2.74 (1.59–4.77) | <0.001  | 2.56 (1.57–5.54) | 0.003   |
| Peak aortic jet velocity (m/s) | 3.08 (1.74–5.44) | <0.001  | 2.95 (1.57–5.54) | 0.001   |
| Diastolic dysfunction (yes/no) | 4.36 (1.74–10.90) | 0.002   | NS                       | NS      |
| Left ventricular mass index (g/m²) | 1.04 (1.01–1.07) | 0.014   | NS                       | NS      |
| Global longitudinal strain (%) | 1.32 (1.09–1.60) | 0.004   | NS                       | NS      |
| Mechanical dispersion (ms) | 1.03 (1.04–1.05) | 0.022   | NS                       | NS      |
| Age (per year) | 1.09 (1.04–1.15) | 0.001   | NS                       | NS      |
| Ejection fraction (%) | 0.94 (0.86–1.03) | 0.172   | NS                       | NS      |
| Relative wall thickness (per 0.01) | 1.05 (1.00–1.09) | 0.048   | NS                       | NS      |
| Systolic blood pressure (mmHg) | 1.01 (0.99–1.03) | 0.262   | NS                       | NS      |

CI, confidence interval; ms, milliseconds; NS, not significant; OR, odds ratio; PP/SVi, pulse pressure/stroke volume index; SD, standard deviation.

References
1. Nkomo VT, Gardin JM, Skelton TN, Gottlieb JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006;368:1005–11.
2. Jung B, Baron G, Butchart EG, Delahaye F, Gohlke-Burwitz F, Levang OW et al. A prospective survey of patients with valvular heart disease in Europe: the Euro heart survey on valvular heart disease. Eur Heart J 2003;24:1231–41.
3. Baumbartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European association of cardiovascular imaging and the American society of echocardiography. J Am Soc Echocardiogr 2017;30:372–92.
4. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Jr, Guyton RA et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2438–88.
5. Hein S, Ammon E, Kostin S, Schönbürg M, Elsaesser A, Polyakova V et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107:984–91.
6. Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuvan AN et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol 2018;71:860–71.
7. Reconditi M, Caremori M, Pinzauti F, Powers JD, Narayanan T, Stienen GJ et al. Myosin filament activation in the heart is tuned to the mechanical task. Proc Natl Acad Sci U S A 2017;114:3240–5.
8. Linani M, Brunello E, Reconditi M, Fusi L, Caremori M, Narayanan T et al. Force generation by skeletal muscle is controlled by mechanosensing in myosin filaments. Nature 2015;528:276–9.
9. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995;26:195–202.
10. Hug J, Cosyns B, Popescu BA, Carstensen HG, Dhal J, Desai MY et al. Distribution and prognostic significance of left ventricular global longitudinal strain in asymptomatic significant aortic stenosis: an individual participant data meta-analysis. JACC Cardiovasc Imaging 2019;12:84–92.
11. Gu H, Li Y, Fok H, Simpson J, Kentish JC, Shah AM et al. Reduced first-phase ejection fraction and sustained myocardial wall stress in hypertensive patients with diastolic dysfunction: a manifestation of impaired shortening deactivation that links systolic to diastolic dysfunction and preserves systolic ejection fraction. Hypertension 2017;69:633–40.
12. Gu H, Saeed S, Boguslavskyi A, Carr-White G, Chambers JB, Chowieczyk P. First-phase ejection fraction is a powerful predictor of adverse events in asymptomatic patients with aortic stenosis and preserved total ejection fraction. JACC Cardiovasc Imaging 2019;12:52–63.
13. Mehta S, Khoury PR, Madsen NL, Dolan LM, Kimball TR, Urbina EM. Arterial thickness and stiffness are independently associated with left ventricular strain. J Am Soc Echocardiogr 2019;31:99–104.

14. Williams B, Mancia G, Spiieri W, Agabiti Rosei E, Azizi M, Burnier M et al. ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. Hypertens 2018;36:1953–2041.

15. Lang RM, Badano LP, Mor-Avi V, Alfalo J, Armstrong A, Ernande L et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2015;28:1–39.

16. Gerds E, Rossebo AB, Pedersen TR, Cioffi G, Lonnebakken MT, Cramariuc D et al. Relation of left ventricular mass to prognosis in initially asymptomatic mild to moderate aortic valve stenosis. Circ Cardiovasc Imaging 2015;8:e003644.

17. de Simone G, Roman MJ, Koren MJ, Mensah GA, Ganau A, Devereux RB. Stroke volume/pulse pressure ratio and cardiovascular risk in arterial hypertension. J Hypertens 1999;17:800–5.

18. Bahlmann E, Cramariuc D, Saeed S, Chambers JB, Nienaber CA, Kuck KH et al. Low systemic arterial compliance is associated with increased cardiovascular morbidity and mortality in aortic valve stenosis. Heart 2019;105:1507–14.

19. Rieck AE, Gerds E, Lonnebakken MT, Bahlmann E, Cioffi G, Gehlikke-Barwolf C et al. Global left ventricular load in asymptomatic aortic stenosis: covariates and prognostic implication (the SEAS trial). Cardiovasc Ultrasound 2012;10:43.

20. Naghelf S, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2016;29:277–314.

21. Bing R, Cavalcante J L, Everett R J, Clavel M A, Newby D E, Dweck M R. Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis. JACC. Cardiovascular Imaging 2019;12:283–96. 10.1016/j.jcmg.2018.11.026

22. Marsan NA, Tops LF, Westenberg JJ, Delgado V, de Roos A, van der Wall EE et al. Usefulness of multimodality imaging for detecting differences in temporal occurrence of left ventricular systolic mechanical events in healthy young adults. Am J Cardiol 2009;104:440–6.

23. Chinos JA, Segers P, Gupta AK, Swillens A, Rietzschel ER, De Buyzere ML et al. Time-varying myocardial stress and systolic pressure-stress relationship: role in myocardial-arterial coupling in hypertension. Circulation 2009;119:2798–807.

24. Greenberg NL, Firstensen MS, Castro PL, Main M, Travaglini A, Odabashian JA et al. Doppler-derived myocardial systolic stress rate is a strong index of left ventricular contractility. Circulation 2002;105:99–105.

25. Wedemann F, Jamal F, Sutherland GR, Ciaus P, Kowalski M, Hatle L et al. Myocardial function defined by strain rate and strain during alterations in isotropic states and heart rate. Am J Physiol Heart Circ Physiol 2002;283:H792–9.

26. Thorstensen A, Dalen H, Amundsen BH, Stoylen A. Peak systolic velocity indices are more sensitive than end-systolic indices in detecting contraction changes assessed by echocardiography in young healthy humans. Eur J Echocardiogr 2011;12:924–30.

27. Dahlé GO, Stangeland L, Moen CA, Salminen PR, Haaverstad R, Møre K et al. The influence of acute unloading on left ventricular strain and strain rate by speckle tracking echocardiography in a pig model. Am J Physiol Heart Circ Physiol 2016;310:H1330–9.

28. Carter-Storch R, Möller JE, Christensen NL, Rasmussen LM, Pedersen R, Sondergard E et al. End-systolic wall stress in aortic stenosis: comparing symptomatic and asymptomatic patients. Open Heart 2019;6:e001021.

29. Kang DH, Park SJ, Rim JH, Yun SC, Kim DH, Song JM et al. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation 2010;121:1502–9.

30. Rieck AE, Cramariuc D, Staal EM, Rossebo AB, Wachtell K, Gerds E. Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). J Hypertens 2010;28:377–83.

31. Roman MJ, Devereux RB, Kizer JR, Okin PM, Lee ET, Wang W et al. High central pulse pressure is independently associated with adverse cardiovascular outcome in the strong heart study. J Am Coll Cardiol 2009;54:1730–4.

32. Mancusi C, Gerds E, de Simone G, Milhso H, Lonnebakken MT, Boman K et al. Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study. Blood Press 2017;26:150–5.

33. Rosca M, Plagne J, Calin A, Popescu BA, Pierard LA, Candelotti P. Impact of aortic stiffness on left ventricular function and B-type natriuretic peptide release in severe aortic stenosis. Eur J Echocardiogr 2011;12:850–6.